ELI LILLY AND COMPANY Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year
ELI LILLY AND COMPANY (LLY) had Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year of $10.00 million as of 2021-06-30, per its 10-Q filed 2021-08-03.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan
us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear · last filed 2021-08-03
- 2021-06-30: Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year $10.00M.
- 2021-03-31: Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year $20.00M.
- 2020-09-30: Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year $5.00M.
- 2020-06-30: Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year $10.00M.
| Period end | Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year |
|---|---|
| 2021-06-30 | $10.00M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $20.00M 10-Q · filed 2021-04-30 |
| 2020-09-30 | $5.00M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $10.00M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $15.00M 10-Q · filed 2020-05-01 |
| 2019-09-30 | $20.00M 10-Q · filed 2019-10-25 |
| 2019-06-30 | $30.00M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $40.00M 10-Q · filed 2019-05-02 |
| 2018-09-30 | $15.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $30.00M 10-Q · filed 2018-07-25 |
| 2018-03-31 | $40.00M 10-Q · filed 2018-04-27 |
| 2017-09-30 | $10.00M 10-Q · filed 2017-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |